153
views
0
recommends
+1 Recommend
0 collections
    8
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Randomized controlled trials (RCTs) are conducted under idealized and rigorously controlled conditions that may compromise their external validity. A literature review was conducted of published English language articles that reported the findings of studies assessing external validity by a comparison of the patient sample included in RCTs reporting on pharmaceutical interventions with patients from everyday clinical practice. The review focused on publications in the fields of cardiology, mental health, and oncology. A range of databases were interrogated (MEDLINE; EMBASE; Science Citation Index; Cochrane Methodology Register). Double-abstract review and data extraction were performed as per protocol specifications. Out of 5,456 de-duplicated abstracts, 52 studies met the inclusion criteria (cardiology, n = 20; mental health, n = 17; oncology, n = 15). Studies either performed an analysis of the baseline characteristics (demographic, socioeconomic, and clinical parameters) of RCT-enrolled patients compared with a real-world population, or assessed the proportion of real-world patients who would have been eligible for RCT inclusion following the application of RCT inclusion/exclusion criteria. Many of the included studies concluded that RCT samples are highly selected and have a lower risk profile than real-world populations, with the frequent exclusion of elderly patients and patients with co-morbidities. Calculation of ineligibility rates in individual studies showed that a high proportion of the general disease population was often excluded from trials. The majority of studies (n = 37 [71.2 %]) explicitly concluded that RCT samples were not broadly representative of real-world patients and that this may limit the external validity of the RCT. Authors made a number of recommendations to improve external validity. Findings from this review indicate that there is a need to improve the external validity of RCTs such that physicians treating patients in real-world settings have the appropriate evidence on which to base their clinical decisions. This goal could be achieved by trial design modification to include a more representative patient sample and by supplementing RCT evidence with data generated from observational studies. In general, a thoughtful approach to clinical evidence generation is required in which the trade-offs between internal and external validity are considered in a holistic and balanced manner.

          Electronic supplementary material

          The online version of this article (doi:10.1186/s13063-015-1023-4) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references82

          • Record: found
          • Abstract: not found
          • Article: not found

          Scoping studies: towards a methodological framework

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials.

            The CONSORT (Consolidated Standards of Reporting Trials) statement is used worldwide to improve the reporting of randomized, controlled trials. Schulz and colleagues describe the latest version, CONSORT 2010, which updates the reporting guideline based on new methodological evidence and accumulating experience.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              The PRECIS-2 tool: designing trials that are fit for purpose.

                Bookmark

                Author and article information

                Contributors
                +44-0-1273 862212 , Tessa@kmho.co.uk
                scurtis@lilly.com
                faries_douglas_e@lilly.com
                srobinson196@btinternet.com
                Johnstonja@lilly.com
                Journal
                Trials
                Trials
                Trials
                BioMed Central (London )
                1745-6215
                3 November 2015
                3 November 2015
                2015
                : 16
                : 495
                Affiliations
                [ ]Kennedy-Martin Health Outcomes Ltd, 3rd Floor, Queensberry House, 106 Queens Road, Brighton, BN1 3XF UK
                [ ]Eli Lilly and Company, Indianapolis, Indiana USA
                Article
                1023
                10.1186/s13063-015-1023-4
                4632358
                26530985
                16ad8497-4d30-4f4d-bdcb-6d09e109e815
                © Kennedy-Martin et al. 2015

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 9 March 2015
                : 21 October 2015
                Categories
                Review
                Custom metadata
                © The Author(s) 2015

                Medicine
                randomized controlled trial,external validity,generalizability,real-world patients,cardiology,mental health,oncology,literature review

                Comments

                Comment on this article